DJ-V-159 is an agonist for G protein-coupled receptor family C group 6 member A (GPRC6A).

DK419 (DK-419) a potent, orally acitve inhibitor of Wnt/β-catenin signaling with IC50 of 0.19 uM in Wnt3A-stimulated TOPFlash assays.

DKFZ-251 (DKFZ251) is a selective inhibitor of Kallikrein-related peptidase 6 (KLK6) with IC50 of 0.13 uM, demonstrates good selectivity for KLK6 compared to other KLKs.

DKFZ-633 (DKFZ633) is a selective inhibitor of Kallikrein-related peptidase 6 (KLK6) with IC50 of 0.25 uM, demonstrates good selectivity for KLK6 compared to other KLKs.

DKM 2-93 is a relatively selective inhibitor of UBA5 with an IC50 of 430 μM.

DKM 3-42 is a selective, covalent, in vivo-active ALDH3A1 inhibitor with IC50 of 50 uM against purified human ALDH3A1, targets ALDH3A1 catalytic cysteine, impairs both in situ and in vivo lung cancer pathogenicity.

DL 071-IT is a potent non-selective beta-adrenoceptor antagonist.

DL-AP4 is a Broad spectrum EAA antagonist.

DL-AP4 sodium salt is a broad spectrum glutamate receptor antagonist..

DL-AP5 is a Broad spectrum EAA antagonist.

DL-AP5 is a Broad spectrum EAA antagonist.

DL-AP7 is a competitive antagonist of the ionotropic glutamate receptor, NMDA.

DL-Carnitine HCl

DLinDMA is a key lipid component of stable nucleic acid lipid particles as a benchmark.

DLin-KC2-DMA is 100-fold and 1000-fold more potent, respectively, in silencing of a hepatic gene (Factor VII) in comparison to the previous generation lipid DLin-DMA.

D-Luciferin is a chemiluminescent substrate of firefly luciferase.

D-Luciferin is a popular bioluminescent substrate of luciferase in the presence of ATP, used in luciferase-based bioluminescence imaging and cell-based high-throughput screening applications. Cas: 2591-17-5

DM1-(PEG)4-DBCO (DBCO-PEG4-DM1) is made by DM1 conjugated to DBCO-(PEG)4 linker.DM1 (mertansine), a thiol-containing maytansinoid, is a potent microtubule-disrupting agent.

DM1-SMe is a potent maytansinoid microtubular inhibitor and an unconjugated DM1 as a mixed disulfide with thiomethane to cap its sulfhydryl group.

DMAT is a potent and specific CK2 inhibitor with an IC50 of 0.13 uM.

DMH1 is a selective BMP receptor inhibitor with IC50 of 107.9 nM for ALK2, exhibiting no inhibition on AMPK, ALK5, KDR (VEGFR-2) or PDGFR.

DMOG is a cell permeable prolyl-4-hydroxylase inhibitor, which upregulates HIF (hypoxia-inducible factor).

DMP 777(L-694458) is a potent, selective, and orally active human leukocyte elastase (HLE) inhibitor.

DM-PIT-1 is a specific PIP3 antagonist that disrupts PIP3/Akt PH domain, PIP3/PDK1 PH domain, and PIP3/GRP1 PH domain with IC50 of 27.1 uM, 80.5 uM, and 35.5 uM, respectively.

DMU2105 is a potent and specific CYP1B1 inhibitor, with IC50s of 10, 742 nM for CYP1B1 and CYP1A1, respectively.

DMU-2105(CYP1B1 inhibitor 7k) is a potent and specific CYP1B1 inhibitor.

DMU-212, a methoxylated resveratrol analog, has significant anticancer activity, and selectively targets tumor cells.

DMX-5804 is a potent, orally active and selective MAP4K4 inhibitor, with an IC50 of 3 nM, a pIC50 of 8.55 for human MAP4K4, less potent on MINK1/MAP4K6 (pIC50, 8.18), and TNIK/MAP4K7 (pIC50, 7.96).

DMXAA (Vadimezan) is a vascular disrupting agents (VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 μM and IC50 of 62.5 μM, respectively. Phase 3.

DNDI-8219 is a novel potent, orally active antileishmanial agent with IC50 of 0.19 uM against Leishmania donovani (L. don).

DNMDP is a potent and selective cancer cell cytotoxic agent that binds to PDE3A, promotes an interaction between PDE3A and Schlafen 12 (SLFN12).

Dnp-GPLG is a peptide for use as a negative control for activity of matrix metalloproteinases (MMPs) that cleave peptides containing the sequence Dnp-GPLG.

Dnp-P-Cha-Abu-Cys(Me)-HA-K(Nma)-NH2 is a fluorogenic substrate for matrix metalloproteinase-1 (MMP-1) and MMP-9.

Dnp-P-Cha-G-Cys(Me)-HA-K(Nma)-NH2 is a fluorogenic substrate for matrix metalloproteinase-1 (MMP-1) and MMP-9

Dnp-PLALWAR is a fluorogenic substrate for matrix metalloproteinase-1 (MMP-1) and MMP-8.

Dnp-PLAYWAR is a fluorogenic substrate for matrix metalloproteinase-8 (MMP-8) and MMP-26.The activity of MMP-8 and MMP-26 can be quantified by measuring tryptophan fluorescence that is unquenched upon peptide hydrolysis that removes the N-terminal dinitro

Dnp-PLG-Cys(Me)-HA-DArg-NH2 is a peptide substrate for matrix metalloproteinase-1 (MMP-1).It has an improved kcat/Km ratio compared with the MMP-1 flurogenic substrate Dnp-PLGLWA-DArg-NH2.

Dnp-PLGMWSR is a fluorogenic substrate for matrix metalloproteinase-2 (MMP-2) and MMP-9.The activity of MMP-2 and MMP-9 can be quantified by measuring tryptophan fluorescence that is unquenched upon peptide hydrolysis that removes the N-terminal dinitroph

Dnp-RPLALWRS is a fluorogenic substrate for matrix metalloproteinase-7 (MMP-7).The activity of MMP-7 can be quantified by measuring tryptophan fluorescence that is unquenched upon peptide hydrolysis that removes the N-terminal dinitrophenol (Dnp) group.

DNQX is a elective non-NMDA antagonist

DNQX is a elective non-NMDA antagonist

DNS-pE (PHGDH Fluorescent Probe DNS-pE) is the first small molecule that can selectively label endogenous 3-phosphoglycerate dehydrogenase (PHGDH) from various mammalian cells.

DNS-pE2 is the first small molecule that can selectively label endogenous 3-phosphoglycerate dehydrogenase (PHGDH) from various mammalian cells.

DO264 is an inhibitor of α/β-hydrolase domain-containing protein 12 (ABHD12; IC50 = 11 nM).It inhibits ABHD12-dependent hydrolysis of lysophosphatidylserine (lyso-PS) in mouse brain membrane lysates (IC50 = 2.8 nM) and human THP-1 cells.

DO34 analog is a triazole DAGL(α) inhibitor extracted from patent WO2017096315 A1, compound 100.

DO-34 is a highly potent dual DAGLα/β inhibitor with IC50 of 6 nM 3-8 nM, respectively.

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

Docetaxel, an analog of taxol, is an inhibitor of depolymerisation of microtubules through binding to stabilized microtubules.

Docosanol (Abreva)

Docosapentaenoic acid (22n-3) is a component of phospholipids found in all animal cell membranes.

Docusate Sodium is a laxative used to treat constipation, for constipation due to the use of opiates it maybe used with a stimulant laxative, can be taken by mouth or rectally.

Dodecanoic acid ingenol ester is a natural compound.

Dodecanoylcarnitine is present in fatty acid oxidation disorders such as long-chain acyl CoA dehydrogenase deficiency, carnitine palmitoyltransferase I/II deficiency, and is also associated with celiac disease.

Dofequidar fumarate(MS-209 fumarate), an orally active quinoline compound, has been reported to overcome MDR by inhibiting ABCB1/P-gp, ABCC1/MDR-associated protein 1, or both.

Dofetilide (Tikosyn)

Dolasetron(MDL-73147) is a serotonin 5-HT3 receptor antagonist used to treat nausea and vomiting following chemotherapy.

Dolutegravir (DTG, GSK1349572) is an integrase inhibitor(IC50= 2.7 nM), modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.

Dolutegravir is a HIV integrase inhibitor with IC50 of 2.7 nM.

Domperidone is a dopamine blocker and an antidopaminergic reagent.

Donepezil is a specific and potent AChE inhibitor for bAChE and hAChE with IC50 of 8.12 nM and 11.6 nM , respectively.

Donepezil(E 2020) is a specific and potent AChE inhibitor for bAChE and hAChE with IC50 of 8.12 nM and 11.6 nM, respectively.

Tavapadon is a potent, orally-bioavailable, selective partial agonist of the dopamine D1 and D5 receptors.

Doravirine (MK-1439) is a non-nucleoside reverse transcriptase inhibitor.

Doripenem Hydrate

Dorrigocin A is a natural compound that shows potent antiproliferative effect on tumor cell line..

Dorsomorphin 2Hcl (Compound C; BML-275) has been shown to act as a potent and selective inhibitor of AMPK (AMP-activated protein kinase; Ki = 109 nM), induced by AICAR and metformin; also inhibits ALK2, ALK3, and ALK 6 .

Dorzolamide HCl is a carbonic anhydrase inhibitor.

Dot1L-IN-1 is a highly potent, selective and structurally novel Dot1L inhibitor with a Ki of 2 pM.

DOTA-ADIBO is a Click Chemistry intermidate used for antibody-drug conjugates..

Dovitinib (TKI258, CHIR-258) is a multitargeted tyrosine kinase inhibitor of FLT3 and c-KIT with IC50 of 1 nM and 2 nM, respectively.

Dovitinib (TKI258, CHIR258) is a novel multi-target inhibitor for Flt3, c-Kit, FGFR1/3, VEGFR1/2/3, PDGFRα/β with IC50 of 1 nM, 2 nM, 8 nM/9 nM and 10 nM/13 nM/8 nM, 210 nM/27 nM respectively.

Dovitinib (TKI258, CHIR258) is a novel multi-target inhibitor for Flt3, c-Kit, FGFR1/3, VEGFR1/2/3, PDGFRα/β with IC50 of 1 nM, 2 nM, 8 nM/9 nM and 10 nM/13 nM/8 nM, 210 nM/27 nM respectively.

Dovitinib(CHIR-258; TKI258) lactate is a potent inhibitor of fibroblast growth factor receptor 3 (FGFR3) with an IC50 of 5 nM.

Doxapram hydrochloride hydrate inhibits TASK-1, TASK-3, TASK-1/TASK-3 heterodimeric channel function with EC50 of 410 nM, 37 μM, 9 μM, respectively.

Doxapram inhibits TASK-1, TASK-3, TASK-1/TASK-3 heterodimeric channel function with EC50 of 410 nM, 37 μM, 9 μM, respectively.

Doxepin HCl is a tricyclic antidepressant that is marketed worldwide.

Doxercalciferol is a synthetic vitamin D2 analog, suppressing parathyroid synthesis and secretion, used to treat secondary hyperparathyroidism and metabolic bone disease.

Doxifluridine(Ro 21-9738; 5'-DFUR) is a thymidine phosphorylase activator for PC9-DPE2 cells with IC50 of 0.62 μM.

Doxorubicin (Adriamycin) is an antibiotic agent that inhibits DNA topoisomerase II and induces DNA damage and apoptosis.

Doxylamine is a first generation antihistamine; can be used by itself as a short-term sedative and in combination with other drugs to provide night-time allergy and cold relief.

Dp44mT is a potent iron chelator, which shows selective antitumor activity.

DPA-714 is a potent, selective ligand for the translocator protein (TSPO) with Ki of 7.0 nM.

DPM-1001 is a potent, selective, orally bioavailable inhibitor of the protein-tyrosine phosphatase PTP1B with IC50 of 100 nM, also chelates copper, which enhanced its potency as a PTP1B inhibitor.

DprE1-IN-2 is a potent DprE1 inhibitor.

DRAinh-A250 is a specific inhibitor of Cl-/anion exchanger SLC26A3 (DRA), fully and reversibly inhibits SLC26A3-mediated Cl- exchange with HCO3-, I-, and thiocyanate (SCN-) with IC50 of ~0.2 uM.

DRAK2-IN-116 is a potent, selective DRAK2 inhibitor with IC50 of 3 nM, shows weak inhibition for DRAK1 (IC50=51 nM) and no significant activity against DAPK1/2/3 (IC50>1 uM)..

DREADD agonist 21 is a potent muscarinic hM3Dq DREADD agonist (EC50 = 1.7 nM). Highly selective for hM3Dq DREADDs over endogenous hM3 receptors.

D-Ribose(mixture of isomers) is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose(mixture of isomers) is active in protein glycation

DRI-C21045 is a novel small-molecule inhibitor of CD40-CD40L protein-protein interaction with IC50 of 0.17 uM in cell-based assays.

Dronedarone is a Class III antiarrhythmic and a multi-channel blocker for atrial fibrillation. It blocks potassium and sodium and is a calcium channel protein inhibitor.

Drospirenone is a synthetic progestogen exhibiting antiandrogenic and antimineralocorticoid activity.

Droxidopa (L-DOPS) is a psychoactive drug and acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline).

Droxinostat is a selective HDAC3, HDAC6 and HDAC8 inhibitor.

DRP1 inhibitor 4 is a selective, small molecule inhibitor of the mammalian mitochondrial division dynamin, DRP1 with IC50 of 1.0 uM, shows no activity against OPA1 and DYN1 (IC50>100 uM)..

DRV1 (GPR32) agonist C2A (NCGC00135472) is a synthetic molecule that activate human resolvin D1 receptor DRV1/GPR32 receptor with EC50 of 0.37 uM and 0.05 uM in β-arrestin and cAMP assays, respectively.

DS-1040 (DS1040) is a small molecule inhibitor of the activated thrombin-activatable fibrinolysis inhibitor (TAFIa) with IC50 of 1.7 ng/mL for rabbit TAFIa.

DS-1040 tosylate (DS1040) is a small molecule inhibitor of the activated thrombin-activatable fibrinolysis inhibitor (TAFIa) with IC50 of 1.7 ng/mL for rabbit TAFIa.

DS-1040 tosylate hydrate (DS1040) is a small molecule inhibitor of the activated thrombin-activatable fibrinolysis inhibitor (TAFIa) with IC50 of 1.7 ng/mL for rabbit TAFIa.

DS16570511 is a cell-permeable inhibitor of the mitochondrial calcium uniporter (MCU) that inhibits serum-induced mitochondrial Ca2+ influx in HEK293A cells with IC50 of 7 uM.

DS-2330 is a phosphorous lowering agent for treating hyperphosphatemia in chronic kidney disease..

DS-2969b (DS 11960558) is a novel orally active GyrB inhibitor, inhibits the supercoiling activity of C. difficile DNA gyrase with IC50 of 20 ng/mL.

Milademetan (DS-3032) is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) induces G1 cell cycle arrest, senescence and apoptosis.

DS42450411 (DS 42450411, DS-42450411) is a potent, orally active hepcidin production inhibitor with IC50 of 32 nM.

DS-437 is a potent, selective, dual inhibitor of PRMT5 and PRMT7 with IC50 of 6.0 uM for both, DS-437 is inactive against 29 other human protein-, DNA-, and RNA-methyltransferases.

DS-6930 (DS 6930, DS6930) is a novel potent, selective PPARγ agonist with EC50 of 41 nM, Emax-68%; significantly recruits several cofactors, such as RIP140 and PGC1, in cofactor recruitment assays; demonstrateshigh PPARγ agonist potency with robust plasma glucose reduction, maintains diminished PPARγ-related adverse effects upon toxicological evaluation in vivo, and demonstrated no hepatotoxicity.

DS-6930b (DS-6930 calcium salt) is the calcium salt of DS-6930, which is a novel potent, selective PPARγ agonist with EC50 of 41 nM, Emax-68%.

DS-70 (α4 integrin inhibitor DS-70) is a novel potent α/β- peptidomimetic antagonist of α4 integrin, binds to integrin α4β1 with nanomolar affinity.

DS-7423 is a novel potent, small-molecule dual inhibitor of PI3K/mTOR with IC50 of 15.6, 1143, 249, 262 and 34.9 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ, and mTOR  respectively.

DS-8500a (DS8500a) is a novel potent, selective, orally available GPR119 agonist with EC50 of 51.5 nM in human GPR119-expressing CHO-K1 cells, displays no significant effect on 66 receptors, channels, or transporters.

DS86760016 is a novel selective bacterial leucyl-tRNA synthetase (LeuRS) inhibitor with IC50 of 0.38 uM (Escherichia coli, LeuRS).

DS88790512 is a potent, selective, and orally bioavailable blocker with IC50 of 11 nM, exhibits excellent selectivity against hERG and hNaV1.5 channels (IC50 >100 uM)..

DS88790512 is a potent, selective, and orally bioavailable blocker with IC50 of 11 nM, exhibits excellent selectivity against hERG and hNaV1.5 channels (IC50 >100 uM)..

Ds-HAPP is an anthrancenyl and dansyl fluorophore ligand.

DSM265 is a PfDHODH inhibitor with an IC50 of 8.9 nM. DSM265 can also inhibit the growth of P. falciparum 3D7 parasites with an EC50 of 4.3 nM.

DSP-0565 (DSP0565) is a new drug candidate with broad anti-convulsant activity, does not bind to any GABA-A binding sites, may be caused as the result of its GABAergic function via novel target..

DSP-1053 is a novel potent serotonin reuptake (SERT) inhibitor with 5-HT1A partial agonistic activity that binds to human serotonin transporter and 5-HT1A receptor with Ki of 1.02 and 5.05 nM, respectively.

DSP-2230 is a selective Nav1.7/Nav1.8 blocker.

DSP-6952 is a novel potent, selective, orally active 5-HT4 receptor partial agonist with Ki of 50-100 nM for human 5-HT4a/4b/4c.

DT204 (DT-204) is a novel SCFSkp2 inhibitor that reduces Skp2 binding to Cullin-1 and Commd1, synergistically enhances BTZ-induced apoptosis.

dTRIM24 is a potent TRIM24 bromodomain inhibitor with IC50 of 217.8 nM (TRIM24 ligand displacement).

Dual BRM and BRG1 inhibitor 14 is a potent, orally active inhibitor of Brahma Homolog (BRM)/SMARCA2 and Brahma-related gene 1 (BRG1) with IC50 of <5 nM for both.

Dual DDR1 and DDR2 inhibitor 5n is a highly potent, selective, dual Discoidin domain receptor DDR1 and DDR2 inhibitor with Kd of 7.9 and 8.0 nM, IC50 of 9.4 and 20.4 nM, repectively.

Duloxetine is a serotonin-norepinephrine reuptake inhibitor with Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD).

Duloxetine is a serotonin-norepinephrine reuptake inhibitor with Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD).

Duocarmycin TM is an exceptionally potent antitumor antibiotic.

Dutasteride is a 5-α-reductase inhibitor that inhibits the conversion of testosterone into dihydrotestosterone (DHT).

DWK-1339|DWK1339|cas 1018946-38-7

DY131(GSK 9089) is a novel selective agonist of ERRβ and ERRγ; displays minimal activity at ERRα, ERα and ERβ at concentrations up to 30 μM.

Dynarrestin is a novel inhibitor of cytoplasmic Dyneins 1 and 2, acts reversibly to inhibit cytoplasmic dynein 1-dependent microtubule binding and motility in vitro without affecting ATP hydrolysis.

Dynasore is a cell-permeable small molecule that inhibits the GTPase activity of dynamin1, dynamin2 and Drp1, the mitochondrial dynamin.

Dynein2-IN-37 (Ciliobrevin analog 37) is a potent, selective cytoplasmic dynein 2 ATPase activity antagonist with IC50 of 11 uM, shows weak inhibition for dynein 2 (IC50=280 uM).

Dyngo-4a is a potent dynamin inhibitor with IC50 of 0.38 μM, 1.1 μM, and 2.3 μM for DynI (brain), DynI (rec), and DynII (rec), respectively.

Dynole 34-2 is a potent dynamin GTPase inhibitor with IC50 of 6.9 and 14.2 uM for full-length dynI and dynII GTPase activity, respectively.

DZ-2384 (DZ2384) is a microtubule-targeting agent, exhibits potent antitumor activity in models of multiple cancer types.

E 2012 is a potent γ-secretase modulator.

E 6201 (E6201) is a potent, selective, dual MEK1 and MEKK1 inhibitor, inhibits LPS-induced TNFα transcription with IC50 of 50 nM.

E 6446 is a novel orally available small molecule inhibitor of TLR7 and TLR9 with IC50 of 1.78 uM and 0.01 uM, respectively.

E1231 (E-1231) is a small molecule SIRT1 activator with EC50 of 0.83 uM, interactes with recombinant human SIRT1 protein and deacetylated liver X receptor-alpha (LXRα).

E260 is a Fer/FerT kinase inhibitor.

E3 Ligand-Linker Conjugate 1 is an E3 ligand- Linker Conjugate for PROTAC.

E3 ligase Ligand 1A is a ligand of E3 ligase, used in PROTAC technology; E3 ligase Ligand 1A can be used in the research of cancer. (S,R,S)-AHPC-Me (VHL ligand 2) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL)

E3 ligase Ligand-Linker Conjugates 16 is a synthesized compound that incorporates an E3 ligase ligand and a linker used in PROTAC technology.

E3 ligase Ligand-Linker Conjugates 17 is a synthesized compound that incorporates an E3 ligase ligand and a linker used in PROTAC technology.

E3330 is a potent and selective APE1(Ref-1) inhibitor, which suppressed NF-kappa B DNA-binding activity.

E-3810 is a novel dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs) with antiangiogenic activity.

E-4031 is a benzenesulfonamide antiarrhythmic agent; blocks the ATP-sensitive potassium channel.

E5555 shows potent inhibitory effects on human platelet aggregation induced by thrombin and TRAP with IC values of 0.064 and 0.031 μM respectively.

E-5842 is a preferential sigma-1 receptor ligand, demonstrates potential atypical antipsychotic effects in vivo.

E-5842 is a preferential sigma-1 receptor ligand, demonstrates potential atypical antipsychotic effects in vivo.

E6005 potently and selectively inhibited human PDE4 activity with an IC50 of 2.8 nM and suppressed the production of various cytokines from human lymphocytes and monocytes with IC50 values ranging from 0.49 to 3.1 nM.

E-64 is a natural, potent, and irreversible inhibitor of cysteine proteases; IC50 values for inhibiting cathepsins K, S, and L, in vitro, are 1.4, 4.1, and 2.5 nM, respectively.

E6446 dihydrochloride is a novel synthetic antagonist for nucleic acid-sensing TLRs; potently suppressed DNA stimulation of HEK:TLR9 cells with IC50 of 10 nM.

E-64c is a synthetic analog of E-64, a potent and irreversible cysteine protease inhibitor isolated from Aspergillus japonicus.

E-64D is an inhibitor of cathepsins B and L; also thought to inhibit calpain,showed a potent activity for COVID-19(SARS-COV-2)with EC50: MERS-COV(1.275),SARS-COV(0.760)

E64FC26 is a highly potent pan-style inhibitor of Protein Disulfide Isomerase (PDI) with IC50 of 1.9 uM (PDIA1), also inhibits all other members of the PDI family, including PDIA3, PDIA4, TXNDC5, and PDIA6.

E67-2 is a potent and selective inhibitor of H3K9 Jumonji demethylase KIAA1718 (KDM7A) with IC50 of 3.4 uM.

E7046 is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM, exhibiting anti-tumor activities.

E-7050 is hepatocyte growth factor receptors (HGFR).

E7080 (Lenvatinib) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β.

E7080 (Lenvatinib; Vargatef) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β.

E7090 (E 7090) is a potent, selective, orally available inhibitor of FGFR1, -2, and -3 with IC50 of 0.71, 0.50 and 1.2 nM, weakly inhibits FGFR4 (IC50=120 nM).

E7090 (E 7090) is a potent, selective, orally available inhibitor of FGFR1, -2, and -3 with IC50 of 0.71, 0.50 and 1.2 nM, weakly inhibits FGFR4 (IC50=120 nM).

E7107 (E-7107) is a derivative of pladienolide that targets the SF3b subunit of the spliceosome, shows significant antitumor activity in vitro and in vivo.

E-7386 (E7386) is a potent, orally active modulator of CBP/beta-catenin, disrupts the interaction and inhibits canonical Wnt signaling pathway /TCF reporter gene activity in LiCl-stimulated HEK-293 and MDA-MB-231 with IC50 of 55 and 73 nM, respectively.

E7449 is an orally bioavailable, potent, small molecule inhibitor of PARP1 and PARP2; enhances the efficacy of radiotherapy and chemotherapy and has potent single agent anticancer activity in BRCA-deficient tumors.

E7820 is an angiogenesis inhibitor by suppressing integrin a2, a cell adhesion molecule expressed on endothelial cells.

EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.

EB1089 is an analog of 1,25 dihydroxyvitamin D which acts as a vitamin D receptor (VDR). EB1089 is noted to reverse hypercalcemia and is a potent inhibitor of PTH-rP (parathyroid hormone-related peptide, PTHRP) in vitro. In studies utilizing a squamous ca

EB-3D is a novel potent and selective choline kinase ChoKα inhibitor with IC50 of 1.0 uM (purified ChoKα1), strongly impairs cell proliferation in a variety of different cancer cell lines.

EBE-A22 is a derivative of PD 153035 which can inhibit ErbB-1-phosphorylation, whereas EBE-A22 is inactive.

EBI-1051 is a novel and orally efficacious MEK inhibitor with IC50 of 10.8 nM against MEK1, inhibits viability of colo-205 cells with IC50 of 4.7 nM.

EBI-2511 is a highly potent and orally active EZH2 inhibitor for the treatment of Non-Hodgkin’s Lymphoma.

EBI-907 is a highly potent, selective, orally active B-Raf V600E inhibitor with enzyme IC50 of 7 nM, A375 cell growth IC50 of 13 nM.

Ebselen is a selenium-based inhibitor of protein kinase C, NADPH, 5-lipoxygenase, cyclooxygenase (COX) and NADPH oxidase.

EC0489, a conjugate of folic acid and desacetyl vinblastine hydrazide, is a high-affinity ligand for the folate receptor (FR). Refractory or metastatic Tumor. Small molecule-drug conjugate (SMDC).

EC330 is a leukemia inhibitory factor (LIF) inhibitor.

EC-359 (EC359) is a first-in-class, orally available inhibitor of leukemia inhibitory factor (LIF), blocks LIF-LIFR interaction and binds to LIFR with affinity of 81 nM in SPR assay.

EC-70124 is a multikinase inhibitor with potent activity against several AML related kinases including FLT3, JAK, SYK or Pim kinases (Kd<10 nM).

Ecabet is an antiulcerative and gastroprotective agent.

Ecdysone

Echinocandin B0

Echinocystic acid  a pentacyclic triterpene isolated from the fruits of Gleditsia sinensis Lam, has potent antioxidant, anti-inflammatory and anti-tumor properties.

Econazole nitrate (Spectazole)

Ecopladib (PLA 725) is a potent, selective and orally active inhibitor of cPLA2α with IC50 of 0.15 and 0.11 uM in GLU micelle and rat whole blood assays, respectively.

Ecteinascidin 770 (ET-770) is a 1,2,3,4-tetrahydroisoquinoline alkaloid with potent anti-cancer activities; inhibits U373MG cells with an IC50 of 4.83 nM.

Edaravone (MCI-186)

Edasalonexent (CAT-1004) is a bifunctional, orally administered small molecule that covalently links 2 compounds known to inhibit NF‐κB, salicylic acid and docosahexaenoic acid (DHA).

Edelfosine is a synthetic lysophospholipid analog that selectively inhibits PLC with IC50 of 9.6 uM in fibroblasts and adenocarcinoma cells.

Edicotinib（JNJ-40346527）is a small molecule and orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R; FMS) with potential antineoplastic activity.

Edivoxetine (LY2216684) is a novel potent, selective norepinephrine reuptake inhibitor (NERI) being evaluated as adjunctive treatment for major depressive disorder (MDD)..

Edivoxetine (LY2216684) is a novel potent, selective norepinephrine reuptake inhibitor (NERI) being evaluated as adjunctive treatment for major depressive disorder (MDD)..

Edonerpic maleate is a novel neurotrophic agent which can inhibit amyloid-β peptides (Aβ).

Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention

Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention

Efaproxiral Sodium is a synthetic allosteric modifier of hemoglobin, used for brain metastases originating from breast cancer.

Efavirenz is a nonnucleoside HIV-1 reverse transcriptase (RT) inhibitor which selectively inhibits the glucuronidation of 3'-Azido-3'-deoxythymidine β-D-glucuronide, Sodium Salt. Studies suggest that Efavirenz binds to a distinct site of reverse transcrip

Efinaconazole(KP-103) is a novel triazole antifungal drug currently under development as a topical treatment for onychomycosis.

Efipladib (PLA 902) is a potent, selective and orally active inhibitor of cPLA2α with IC50 of 20 nM for LTB4 inhibition.

Eflornithine(Difluoromethylornithine) inhibits polyamine biosynthesis by the selective, irreversible inhibition of ornithine decarboxylase (ODC). A chemoprotective agent that blocks angiogenesis. Its biological half-life is 8 hours.

Efonidipine(NZ-105) Hcl monoethanolate is a dual T-type and L-type calcium channel blocker (CCB).